HBR IdeaCast CEO Series: 23andMe’s Anne Wojcicki on Scientific Breakthroughs and Public Trust
May 20, 2021
Anne Wojcicki, CEO of 23andMe, is a visionary in DNA testing and personalized medicine. She discusses the challenges of leading a groundbreaking company at the intersection of science and consumer trust. Wojcicki highlights the importance of transparency in data privacy, enabling informed choices. She also shares insights on the role of genetic research during the COVID-19 pandemic, revealing intriguing findings about blood type O. Lastly, she reflects on the competitive landscape of genetic testing and the potential of direct-to-consumer healthcare in improving personal health decisions.
AI Snips
Chapters
Transcript
Episode notes
Regulatory Shifts
- Initially, 23andMe wasn't classified as a medical device, but this changed with the Obama administration.
- This highlights the dynamic nature of regulations, especially in emerging industries.
Maintaining Focus
- Focus on your long-term vision.
- Share positive customer stories to maintain team motivation during challenges.
Building Trust and Transparency
- Build trust by being transparent.
- Give users clear choices about their data.